Moulins

Researchers are studying patients with severe obesity who are undergoing or have considered bariatric surgery to understand how psychological factors affect changes in body weight after surgery. This study collects data from patients who completed the Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) questionnaire before surgery and tracks their body mass index (BMI) over time. The study aims to identify risk factors such as depression, anxiety, eating disorders, quality of life, satisfaction, and body perception that might influence surgery outcomes and help tailor therapies to improve success. The study includes two phases of data collection. The first phase gathers preoperative psychological and clinical data using the MMPI-2-RF questionnaire during consultations before surgery. The second phase collects postoperative data during routine follow-up visits in the nutrition department, where patients complete additional psychological questionnaires including the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder (GAD-7) scale, Three Factor Eating Questionnaire (TFEQ-R21), Quality of Life for Obesity and Dietetic Questionnaire (EQVOD), Body Esteem Scale (BES), and Figure Rating Scale. Participants are involved through preoperative psychological assessments and postoperative follow-ups with repeated questionnaires to monitor psychological health and BMI changes. The main outcome measured is how depressive symptoms predict the evolution of BMI. Data collection spans from initial preoperative assessment through postoperative consultations, with continuous evaluation of psychological factors and body weight changes to improve bariatric surgery success and patient care.

Sepsis is a serious condition caused by the body's uncontrolled response to infection, leading to organ failure and potentially death. Septic shock is its most severe form, marked by low blood pressure and poor tissue oxygenation. Current guidelines recommend using serum lactate levels to guide early treatment, but lactate may not always directly reflect tissue blood flow. Researchers are investigating whether measuring the difference in carbon dioxide levels between venous and arterial blood (CO2 gap) can better guide treatment and improve survival in septic shock patients. This study compares two early resuscitation strategies in adults with septic shock: one guided by the venous-to-arterial CO2 gap and the other guided by lactate levels. Patients in the CO2 gap group will have blood sampled via central venous catheters for CO2 analysis, and treatments such as dobutamine or blood transfusions may be adjusted based on oxygen deficiency signs. The goal is to see if CO2 gap-guided care can reduce death rates compared to lactate-guided care. Participants will be closely monitored daily for 28 days after randomization to assess survival. Clinical evaluations, blood tests, and other assessments will be conducted to measure treatment response and organ function. The study focuses on all-cause mortality at 28 days as the primary outcome to determine which resuscitation method better supports recovery in septic shock patients.

Neuropathic pain related to cancer and its treatments such as surgery, chemotherapy, and radiotherapy can cause acute and chronic pain that affects quality of life. Around 58% of cancer patients experience chronic neuropathic pain, which is often hard to treat and can persist after cancer remission. Many factors like preoperative pain intensity, opioid use, age, sleep problems, and psychological vulnerability influence chronic pain development, but there is currently no simple tool to predict individual risk before treatment begins. This research collects cognitive-emotional and pain-related data through questionnaires to validate a predictive tool that helps estimate the risk of neuropathic pain in cancer patients. The focus is on patients with breast, gynecological, colorectal, or lung cancer who are about to undergo anticancer therapies such as chemotherapy, surgery, hormonal therapy, radiotherapy, or targeted therapy. The study aims to optimize treatment by identifying patients more vulnerable to developing chronic neuropathic pain. Participants provide data through assessments of cognitive-emotional states and pain parameters. The main outcomes measured are CANoPy scores at baseline, 6 months, and 12 months to track pain progression. Patients must understand and cooperate with study requirements and give oral consent. The study also includes healthy volunteers for comparison. Participants are monitored throughout the study to evaluate the predictive tool's ability to identify those at risk of chronic neuropathic pain.